Targeting CD20 in chronic lymphocytic leukemia
Myrna R Nahas, Jon E ArnasonBeth Israel Deaconess Medical Center, Boston, MA, USAAbstract: Chronic lymphocytic leukemia (CLL), the most common leukemia in adults, is standardly managed with chemotherapy in combination with the anti-CD20 antibody rituximab. In this review, we discuss the history, us...
Saved in:
Main Authors: | Nahas MR, Arnason JE |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2015
|
Subjects: | |
Online Access: | https://doaj.org/article/5553e19ee40f47e3a977ac5250db6693 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The expanding role of bendamustine in chronic lymphocytic leukemia
by: Nair KS, et al.
Published: (2015) -
Coexistence of primary myelofibrosis and chronic lymphocytic leukemia
by: Burgstaller S, et al.
Published: (2014) -
Pharmacology and clinical potential of oblimersen sodium in the treatment of chronic lymphocytic leukemia
by: O'Brien S, et al.
Published: (2012) -
Treating the elderly patient with chronic lymphocytic leukemia: current and emerging options
by: Mozaheb Z
Published: (2014) -
Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives [Erratum]
by: Anagnostou T, et al.
Published: (2018)